Skip to main content

News about Scitation

In December 2016 Scitation will launch with a new design, enhanced navigation and a much improved user experience.

To ensure a smooth transition, from today, we are temporarily stopping new account registration and single article purchases. If you already have an account you can continue to use the site as normal.

For help or more information please visit our FAQs.

banner image
No data available.
Please log in to see this content.
You have no subscription access to this content.
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.
/content/avs/journal/bip/8/1/10.1186/1559-4106-8-33
1.
1.D Butler, UN targets top killers, Nature 477, 260 (2011).
2.
2.S Sanon, DJ Lenihan and E Mouhayar, Peripheral arterial ischemic events in cancer patients, Vasc Med 16, 119 (2011).
3.
3.AB Lumsden, MG Davies and EK Peden, Medical and endovascular management of critical limb ischemia, J Endovasc Ther 16, II31 (2009).
4.
4.J Aoki, AJ Lansky and R Mehran et al., Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the acute catheterization and urgent intervention triage strategy trial, Circulation 119, 687 (2009).
5.
5.F Jung, C Wischke and A Lendlein, Degradable, multifunctional cardiovascular implants: challenges and hurdles, MRS Bull 35, 607 (2011).
6.
6.P Erne, M Schier and TJ Resink, The road to bioabsorbable stents: reaching clinical reality?, Cardiovasc Intervent Radiol 29, 11 (2006).
7.
7.M Joner, AV Finn and A Farb et al., Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk, J Am Coll Cardiol 48, 193 (2006).
8.
8.ML Rossi, D Zavalloni, GL Gasparini and P Presbitero, Very late multivessel thrombosis of bare metal stents with concomitant patent drug-eluting stents after withdrawal of aspirin, Int J Cardiol 131, e7 (2008).
9.
9.M Desai, AM Seifalian and G Hamilton, Role of prosthetic conduits in coronary artery bypass grafting, Eur J cardio-thoracic Surg 40, 394 (2011).
10.
10.J-W Park, B Leithäuser and U Gerk et al., Percutaneous left atrial appendage transcatheter occlusion (PLAATO) for stroke prevention in atrial fibrillation: 2-year outcomes, J Invasive Cardiol 21, 446 (2009).
11.
11.FJ Schoen and RF Padera Jr, Biomaterials Science - An Introduction to Materials in Medicine, edited by BD Ratner, A Hoffman, FJ Schoen and JE Lemons (Elsevier Academic Press, Amsterdam, Heidelberg [a.o.], 2013) 3 p. 761.
12.
12.DB Sims, H Takayama and N Uriel et al., Ventricular assist device-associated thrombus, Circulation 124, e197 (2011).
13.
13.Y Song, J Feijen, DW Grijpma and AA Poot, Tissue engineering of small-diameter vascular grafts: a literature review, Clin Hemorheol Microcirc 49, 357 (2011).
14.
14.B Sivaraman and R Latour, The relationship between platelet adhesion on surfaces and the structure versus the amount of adsorbed fibrinogen, Biomaterials 31, 832 (2010).
15.
15.B Sivaraman and R Latour, The adherence of platelets to adsorbed albumin by receptor-mediated recognition of binding sites exposed by adsorption-induced unfolding, Biomaterials 31, 1036 (2010).
16.
16.P Tengvall, Protein Interactions with Biomaterials, Compr. Biomater (Elsevier Ltd., Oxford, 2011) p. 63.
17.
17.K Yu, BFL Lai and JN Kizhakkedathu, Carbohydrate structure dependent hemocompatibility of biomimetic functional polymer brushes on surfaces, Adv Healthc Mater 1, 199 (2012).
18.
18.X Cheng, HE Canavan and DJ Graham et al., Temperature dependent activity and structure of adsorbed proteins on plasma polymerized N-isopropyl acrylamide, Biointerphases 1, 61 (2006).
19.
19.K Jurk and BE Kehrel, Platelets: physiology and biochemistry, Semin Thromb Hemost 31, 381 (2005).
20.
20.T Gori, Viscosity, platelet activation, and hematocrit: progress in understanding their relationship with clinical and subclinical vascular disease, Clin Hemorheol Microcirc 49, 37 (2011).
21.
21.A Weyrich, F Cipollone, A Mezzetti and G Zimmerman, Platelets in atherothrombosis: new and evolving roles, Curr Pharm Des 13, 1685 (2007).
22.
22.JW Semple, JE Italiano and J Freedman, Platelets and the immune continuum, Nat Rev Immunol 11, 264 (2011).
23.
23.WH Reinhart, Platelets in vascular disease, Clin Hemorheol Microcirc 53, 71 (2013).
24.
24.AT Nurden, Platelets, inflammation and tissue regeneration, Thromb Haemost 105(Suppl), S13 (2011).
25.
25.MV Sefton, Biomaterials science: an introduction to materials in medicine, edited by BD Ratner, AS Hoffman, FJ Schoen and JE Lemons (Elsevier Academic Press [a.o.], Amsterdam, Heidelberg, 2012) 3 p. 785.
26.
26.BD Ratner, Biomaterials science: an introduction to materials in medicine (Elsevier, Academic Pr, Amsterdam, Heidelberg [a.o.], 2012) 3.
27.
27.BD Ratner, The blood compatibility catastrophe, J Biomed Mater Res 27, 283 (1993).
28.
28.BD Ratner, The catastrophe revisited: blood compatibility in the 21st century, Biomaterials 28, 5144 (2007).
29.
29.U Seyfert, In vitro hemocompatibility testing of biomaterials according to the ISO 10993–4, Biomol Eng 19, 91 (2002).
30.
30.P Thevenot, W Hu and L Tang, Surface chemistry influences implant biocompatibility, Curr Top Med Chem 8, 270 (2008).
31.
31.JM Anderson, A Rodriguez and DT Chang, Foreign body reaction to biomaterials, Semin Immunol 20, 86 (2008).
32.
32.JM Anderson, Inflammatory response to implants, ASAIO Trans Am Soc Artif Intern Organs 34, 101 (1988).
33.
33.A Marmur, Solid-surface characterization by wetting, Annu Rev Mater Res 39, 473 (2009).
34.
34.B Hiebl, K Lützow and M Lange et al., Cytocompatibility testing of cell culture modules fabricated from specific candidate biomaterials using injection molding, J Biotechnol 148, 76 (2010).
35.
35.D Rickert, A Lendlein and AM Schmidt et al., In vitro cytotoxicity testing of AB-polymer networks based on oligo(epsilon-caprolactone) segments after different sterilization techniques, J Biomed Mater Res B Appl Biomater 67, 722 (2003).
36.
36.T Roch, BF Pierce and A Zaupa et al., Reducing the endotoxin burden of desaminotyrosine- and desaminotyrosyl tyrosine-functionalized gelatin, Macromol Symp 309–310, 182 (2011).
37.
37.R Lieder, PH Petersen and OE Sigurjónsson, Endotoxins - the invisible companion in biomaterials research, Tissue Eng Part B Rev 19, 391 (2013).
38.
38.MB Gorbet and MV Sefton, Endotoxin: the uninvited guest, Biomaterials 26, 6811 (2005).
39.
39.S Franz, S Rammelt, D Scharnweber and JC Simon, Immune responses to implants - a review of the implications for the design of immunomodulatory biomaterials, Biomaterials 32, 6692 (2011).
40.
40.O Takeuchi and S Akira, Pattern recognition receptors and inflammation, Cell 140, 805 (2010).
41.
41.MT Rondina, AS Weyrich and GA Zimmerman, Platelets as cellular effectors of inflammation in vascular diseases, Circ Res 112, 1506 (2013).
42.
42.T Roch, J Cui and K Kratz et al., Immuno-compatibility of soft hydrophobic poly (n-butyl acrylate) networks with elastic moduli for regeneration of functional tissues, Clin Hemorheol Microcirc 50, 131 (2012).
43.
43.CF Jones and DW Grainger, In vitro assessments of nanomaterial toxicity, Adv Drug Deliv Rev 61, 438 (2009).
44.
44.M Yliperttula, BG Chung and A Navaladi et al., High-throughput screening of cell responses to biomaterials, Eur J Pharm Sci 35, 151 (2008).
45.
45.A Krüger, S Braune and K Kratz et al., The influence of poly(n-butyl acrylate) networks on viability and function of smooth muscle cells and vascular fibroblasts, Clin Hemorheol Microcirc 52, 283 (2012).
46.
46.C Wischke, A Krüger and T Roch et al., Endothelial cell response to (co)polymer nanoparticles depending on the inflammatory environment and comonomer ratio, Eur J Pharm Biopharm 84, 288 (2013).
47.
47.S Li and JJD Henry, Nonthrombogenic approaches to cardiovascular bioengineering, Annu Rev Biomed Eng 13, 451 (2011).
48.
48.N Scharnagl, B Hiebl and K Trescher et al., Behaviour of fibroblasts on water born acrylonitrile-based copolymers containing different cationic and anionic moieties, Clin Hemorheol Microcirc 52, 295 (2012).
49.
49.MA Cooperstein and HE Canavan, Assessment of cytotoxicity of (N-isopropyl acrylamide) and poly(N-isopropyl acrylamide)-coated surfaces, Biointerphases 8, 19 (2013).
50.
50.K Trescher, T Roch and J Cui et al., Test system for evaluating the influence of polymer properties on primary human keratinocytes and fibroblasts in mono- and coculture, J Biotechnol 166, 58 (2013).
51.
51.W Van Oeveren, Obstacles in haemocompatibility testing, Scientifica (Cairo) 2013, 1 (2013).
52.
52.F Jung, S Braune and A Lendlein, Haemocompatibility testing of biomaterials using human platelets, Clin Hemorheol Microcirc 53, 97 (2013).
53.
53.HM Oudemans-van Straaten, JA Kellum and R Bellomo, Clinical review: anticoagulation for continuous renal replacement therapy - heparin or citrate?, Crit Care 15, 202 (2011).
54.
54.SA Mousa, Methods Mol Biol (2010).
55.
55.BD Ratner, AS Hoffman, FJ Schoen and JE Lemons, Biomaterials Science - An Introduction to Materials in Medicine (Elsevier Academic Press, Amsterdam, Heidelberg [a.o.], 2004) 2 p. 913.
56.
56.OA Hamad, PH Nilsson and D Wouters et al., Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1, J Immunol 184, 2686 (2010).
57.
57.F Bexborn, AE Engberg and K Sandholm et al., Hirudin versus heparin for use in whole blood in vitro biocompatibility models, J Biomed Mater Res A 89, 951 (2009).
58.
58.M Alquwaizani, L Buckley, C Adams and J Fanikos, Anticoagulants: a review of the pharmacology, dosing, and complications, Curr Emerg Hosp Med Rep 1, 83 (2013).
59.
59.H Bussey, JL Francis and TH Consensus Group, Heparin overview and issues, Pharmacotherapy 24, 103S (2004).
60.
60.X Chang and M Gorbet, The effect of shear on in vitro platelet and leukocyte material-induced activation, J Biomater Appl 28, 407 (2013).
61.
61.C Sperling, MF Maitz and S Talkenberger et al., In vitro blood reactivity to hydroxylated and non-hydroxylated polymer surfaces, Biomaterials 28, 3617 (2007).
62.
62.HP Wendel, N Hauser, F Briquet and G Ziemer, Hemocompatibility of medical connectors with biopassive or bioactive surface coatings, J Biomater Appl 17, 5 (2002).
63.
63.A Waterhouse, Y Yin and SG Wise et al., The immobilization of recombinant human tropoelastin on metals using a plasma-activated coating to improve the biocompatibility of coronary stents, Biomaterials 31, 8332 (2010).
64.
64.B Nilsson, KN Ekdahl, TE Mollnes and JD Lambris, The role of complement in biomaterial-induced inflammation, Mol Immunol 44, 82 (2007).
65.
65.I Mackie, P Cooper and A Lawrie et al., Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis, Int J Lab Hematol 35, 1 (2013).
66.
66.M Cattaneo, C Cerletti and P Harrison et al., Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH, J Thromb Haemost 11, 1183 (2013).
67.
67.M Cattaneo, CPM Hayward and KA Moffat et al., Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH, J Thromb Haemost 7, 1029 (2009).
68.
68.A Koster, K-G Fischer, S Harder and F Mertzlufft, The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT, Biol Targets Ther 1, 105 (2007).
69.
69.R Kopp, R Bernsberg and A Kashefi et al., Effect of hirudin versus heparin on hemocompatibility of blood contacting biomaterials: an in vitro study, Int J Artif Organs 28, 1272 (2005).
70.
70.J Vienken, The need for a systems approach in biomaterials testing, Med Device Technol 18(12–4), 16 (2007).
71.
71.G Lippi, GL Salvagno and M Montagnana et al., Quality standards for sample collection in coagulation testing, Semin Thromb Hemost 38, 565 (2012).
72.
72.KJ Smock, RA Crist and SJ Hansen et al., Discard tubes are not necessary when drawing samples for specialized coagulation testing, Blood Coagul Fibrinolysis an Int J Haemost Thromb 21, 279 (2010).
73.
73.MTM Raijmakers, CHF Menting, HL Vader and F Van Der Graaf, Collection of blood specimens by venipuncture for plasma-based coagulation assays: necessity of a discard tube, Am J Clin Pathol 133, 331 (2010).
74.
74.M Cole, L Price and A Parry et al., A study to determine the minimum volume of blood necessary to be discarded from a central venous catheter before a valid sample is obtained in children with cancer, Pediatr Blood Cancer 48, 687 (2007).
75.
75.ML Kalb, L Potura, G Scharbert and SA Kozek-Langenecker, The effect of ex vivo anticoagulants on whole blood platelet aggregation, Platelets 20, 7 (2009).
76.
76.DM Adcock, DM Hoefner and K Kottke-Marchant et al., Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays and molecular hemostasis assays: approved guideline, CLSI document H21-A5 (ISBN 1-56238-657-3) (Wayne, Pennsylvania, 2008) 5 p. 6.
77.
77.D Adcock, D Kressin and RA Marlar, The effect of time and temperature variables on routine coagulation tests, Blood Coagul Fibrinolysis 9, 463 (1998).
78.
78.LV Rao, AO Okorodudu, JR Petersen and MT Elghetany, Stability of prothrombin time and activated partial thromboplastin time tests under different storage conditions, Clin Chim Acta 300, 13 (2000).
79.
79.HK Breddin, Can platelet aggregometry be standardized?, Platelets 16, 151 (2005).
80.
80.MG Cohen, JS Rossi and J Garbarino et al., Insights into the inhibition of platelet activation by omega-3 polyunsaturated fatty acids: beyond aspirin and clopidogrel, Thromb Res 128, 335 (2011).
81.
81.G Endler, G Slavka, T Perkmann and A Haushofer, The importance of preanalytics for the coagulation laboratory, Haemostaseologie 30, 63 (2010).
82.
82.EJ Favaloro, DM Adcock Funk and G Lippi, Pre-analytical variables in coagulation testing associated with diagnostic errors in hemostasis, Lab Med 43, 1 (2012).
83.
83.M Böhm, S Täschner and E Kretzschmar et al., Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von willebrand factor: potential for misdiagnosis of haemophilia and von willebrand disease, Blood Coagul Fibrinolysis an Int J Haemost Thromb 17, 39 (2006).
84.
84.EJ Favaloro, S Soltani and J McDonald, Potential laboratory misdiagnosis of hemophilia and von willebrand disorder owing to cold activation of blood samples for testing, Am J Clin Pathol 122, 686 (2004).
85.
85.KH Polderman, Hypothermia and coagulation, Crit Care 16, A20 (2012).
86.
86.A Straub, M Breuer and HP Wendel et al., Critical temperature ranges of hypothermia-induced platelet activation: possible implications for cooling patients in cardiac surgery, Thromb Haemost 97, 608 (2007).
87.
87.A Straub, S Krajewski and JD Hohmann et al., Evidence of platelet activation at medically used hypothermia and mechanistic data indicating ADP as a key mediator and therapeutic target, Arterioscler Thromb Vasc Biol 31, 1607 (2011).
88.
88.K Breddin, In-vitro-Methoden zur Beurteilung der Plättchenfunktion, Blut 18, 84 (1968).
89.
89.RD Frank, H Dresbach, H Thelen and HG Sieberth, Glutardialdehyde induced fluorescence technique (GIFT): a new method for the imaging of platelet adhesion on biomaterials, J Biomed Mater Res 52, 374 (2000).
90.
90.S Braune, A Hönow and C Mrowietz et al., Hemocompatibility of soft hydrophobic poly(n-butyl acrylate) networks with elastic moduli adapted to the elasticity of human arteries, Clin Hemorheol Microcirc 49, 375 (2011).
91.
91.S Braune, G Alagöz and B Seifert et al., Automated image-based analysis of adherent thrombocytes on polymer surfaces, Clin Hemorheol Microcirc 52, 349 (2012).
92.
92.M Lange, S Braune and K Luetzow et al., Surface functionalization of poly(ether imide) membranes with linear, methylated oligoglycerols for reducing thrombogenicity, Macromol Rapid Commun 33, 1487 (2012).
93.
93.HL Goldsmith, DN Bell and S Braovac et al., Physical and chemical effects of red cells in the shear-induced aggregation of human platelets, Biophys J 69, 1584 (1995).
94.
94.HL Goldsmith, SS Yu and J Marlow, Fluid mechanical stress and the platelet, Thromb Diath Haemorrh 34, 32 (1975).
95.
95.H Schmid-Schonbein, H Rieger and T Fischer, Blood fluidity as a consequence of red cell fluidity: flow properties of blood and flow behavior of blood in vascular diseases, Angiology 31, 301 (1980).
96.
96.DR Phillips, W Teng and A Arfsten et al., Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate, Circulation 96, 1488 (1997).
97.
97.PG Kalman, DA McCullough and CA Ward, Evacuation of microscopic air bubbles from dacron reduces complement activation and platelet aggregation, J Vasc Surg 11, 591 (1990).
98.
98.W Lemm, The Reference Materials of the European Communities: Results of Hemocompatibility Tests (Springer, Berlin, Heidelberg, 1992).
99.
99.The European Society for Biomaterials, , 9th european conference on biomaterials chester, UK 9-11th september, 1991 in conjunction with 2nd consensus conference on definitions in biomaterials 7-8th september, 1991 and IUPAC working party on blood compatibility, J Mater Sci Mater Med 2, 62 (1991).
100.
100.JL Brash and P Ten Hove, Protein adsorption studies on “standard” polymeric materials, J Biomater Sci Polym Ed 4, 591 (1993).
101.
101.MC Bélanger and Y Marois, Hemocompatibility, biocompatibility, inflammatory and in vivo studies of primary reference materials low-density polyethylene and polydimethylsiloxane: a review, J Biomed Mater Res 58, 467 (2001).
102.
102.A Hansen, L McMillan and A Morrison et al., Polymers for the rapid and effective activation and aggregation of platelets, Biomaterials 32, 7034 (2011).
103.
103.K Kottke-Marchant and D Bruce, Laboratory Hematology Practice (Wiley-Blackwell, Chichester, Hoboken, 2012) p. 776.
104.
104.R Hoffman, EJB Jr and LE Silberstein et al., Hematology: Basic Principles and Practice (Churchill Livingstone Elsevier, Philadelphia, 2012) 6.
105.
105.CS Kitchens, BA Konkle and CM Kessler, Consultative Hemostasis and Thrombosis (Saunders Elsevier, Philadelphia, 2013) 3.
106.
106.J Myerson, L He and G Lanza et al., Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis, J Thromb Haemost 9, 1292 (2011).
107.
107.JM Koziara, JJ Oh and WS Akers et al., Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles, Pharm Res 22, 1821 (2005).
108.
108.JL Brash and S Uniyal, Dependence of albumin-fibrinogen simple and competitive adsorption on surface properties of biomaterials, J Polym Sci Polym Symp 66, 377 (1979).
109.
109.JL Brash, Exploiting the current paradigm of blood-material interactions for the rational design of blood-compatible materials, J Biomater Sci Polym Ed 11, 1135 (2000).
110.
110.RM Cornelius, SP Shankar, JL Brash and JE Babensee, Immunoblot analysis of proteins associated with self-assembled monolayer surfaces of defined chemistries, J Biomed Mater Res A 98, 7 (2011).
111.
111.M Rabe, D Verdes and S Seeger, Understanding protein adsorption phenomena at solid surfaces, Adv Colloid Interface Sci 162, 87 (2011).
112.
112.N Weber, HP Wendel and G Ziemer, Hemocompatibility of heparin-coated surfaces and the role of selective plasma protein adsorption, Biomaterials 23, 429 (2002).
113.
113.MB Gorbet and MV Sefton, Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes, Biomaterials 25, 5681 (2004).
114.
114.M Levy and AR Hartman, Heparin-coated bypass circuits in cardiopulmonary bypass: improved biocompatibility or not, Int J Cardiol 53(Suppl), S81 (1996).
115.
115.T Wiedmer, SJ Shattil, M Cunningham and PJ Sims, Role of calcium and calpain in complement-induced vesiculation of the platelet plasma membrane and in the exposure of the platelet factor Va receptor, Biochemistry 29, 623 (1990).
116.
116.H Neubauer, P Setiadi and A Pinto et al., Upregulation of platelet CD40, CD40 ligand (CD40L) and P-selectin expression in cigarette smokers: a flow cytometry study, Blood Coagul Fibrinolysis 20, 694 (2009).
117.
117.CH Gemmell, MV Sefton and EL Yeo, Platelet-derived microparticle formation involves glycoprotein IIb-IIIa, inhibition by RGDS and a Glanzmann’s thrombasthenia defect, J Biol Chem 268, 14586 (1993).
118.
118.BZ Galper and L Mauri, Antiplatelet therapy after coronary stenting, Curr Treat Options Cardiovasc Med 15, 1 (2013).
119.
119.K Görlinger, L Bergmann and D Dirkmann, Coagulation management in patients undergoing mechanical circulatory support, Best Pract Res Clin Anaesthesiol 26, 179 (2012).
120.
120.MJ Cho, J Liu and TI Pestina et al., The roles of alpha IIb beta 3-mediated outside-in signal transduction, thromboxane A2, and adenosine diphosphate in collagen-induced platelet aggregation, Blood 101, 2646 (2003).
http://aip.metastore.ingenta.com/content/avs/journal/bip/8/1/10.1186/1559-4106-8-33
Loading
/content/avs/journal/bip/8/1/10.1186/1559-4106-8-33
Loading

Data & Media loading...

Loading

Full text loading...

true

Access Key

  • FFree Content
  • OAOpen Access Content
  • SSubscribed Content
  • TFree Trial Content
752b84549af89a08dbdd7fdb8b9568b5 journal.articlezxybnytfddd
/content/realmedia?fmt=ahah&adPositionList=
&advertTargetUrl=//oascentral.aip.org/RealMedia/ads/&sitePageValue=avspublications.org/8/1/10.1186/1559-4106-8-33&pageURL=http://scitation.aip.org/content/avs/journal/bip/8/1/10.1186/1559-4106-8-33'
Right1,Right2,Right3,